A Phase 3 interventional study of Sirolimus (Rapamune®) in Renal Transplant, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 9 sites in Korea, Republic of. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2010-04-28.
Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Primary : To evaluate the efficacy of sirolimus assessed by the incidence of biopsy-confirmed acute rejection episode at 6 months after transplantation in Korean renal transplantation recipients.
Secondary :
Wyeth is now a wholly owned subsidiary of Pfizer is the lead sponsor of 484 studies on the registry; none are open to participants now.
First submitted before Wyeth became part of Pfizer.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation.
The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).
Time frame: 6 months after transplantation
Glomerular Filtration Rate (GFR) (Nankivell Method)
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using the Nankivell formula. A normal GFR is \>90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poorer kidney function. A GFR \<15 is consistent with kidney failure.
Time frame: 6 and 12 months
Serum Creatinine
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.
Time frame: Baseline, 6 and 12 months
Patient and Graft Survival
Patient survival defined as patients living with or without a functioning graft. Graft survival defined as those patients who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
Time frame: 12 months
Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 12 After Transplantation
The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).
Time frame: 12 months after transplantation
Patients were recruited in Korea from March 2007 to November 2007.
| Milestone | Sirolimus (SRL) |
|---|---|
| Started | 79 |
| Completed | 59 |
| Not completed | 20 |
| Withdrew: Adverse event | 1 |
| Withdrew: Serious adverse event | 14 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Protocol violation | 3 |
The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).
| patients | Sirolimus (SRL) |
|---|---|
| Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 6 After Transplantation. | 12 |
GFR is an index of kidney function. GFR describes the flow rate of filtered fluid through the kidney. GFR can be measured directly or estimated using established formulas. For this study, GFR was calculated using the Nankivell formula. A normal GFR is \>90 mL/min, although children and older people usually have a lower GFR. Lower values indicate poorer kidney function. A GFR \<15 is consistent with kidney failure.
| mL/min | Sirolimus (SRL) |
|---|---|
| 6 months | 67.36 ± 15.25 |
| 12 months | 71.92 ± 18.82 |
Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. An increased level of creatinine in the blood indicates decreased kidney function. Normal adult blood levels of creatinine are 0.5 to 1.1 mg/dL for females and 0.6 to 1.2 mg/dL for males; however, the normal values are age-dependent as elderly patients typically have smaller muscle mass.
| mg/dl | Sirolimus (SRL) |
|---|---|
| Baseline | 9.42 ± 3.64 |
| 6 months | 1.30 ± 0.36 |
| 12 months | 1.25 ± 0.43 |
Patient survival defined as patients living with or without a functioning graft. Graft survival defined as those patients who did not experience graft loss. Graft loss defined as physical loss (nephrectomy), functional loss (necessitating maintenance dialysis for \>8 weeks), retransplant or death during the first 12 months after randomization.
| patients | Sirolimus (SRL) |
|---|---|
| Patient survival 6 months | 77 |
| Patient survival 12 months | 76 |
| Graft survival 6 months | 77 |
| Graft survival 12 months | 76 |
The diagnosis of acute rejection required a kidney biopsy. Biopsies were assessed using the Banff criteria, standardized diagnostic categories based on histological assessments (e.g., cell types and distributions).
| patients | Sirolimus (SRL) |
|---|---|
| Number of Patients Experiencing Biopsy Confirmed Acute Rejection Through Month 12 After Transplantation | 15 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sirolimus (SRL) | — | 39/79 (49.4%) | 79/79 (100%) |
| Event | Sirolimus (SRL) |
|---|---|
| Blood creatinine increasedInvestigations | 10/79 |
| Herpes zosterInfections and infestations | 6/79 |
| LymphoceleVascular disorders | 6/79 |
| PneumoniaInfections and infestations | 5/79 |
| DiarrhoeaGastrointestinal disorders | 3/79 |
| DeathGeneral disorders | 3/79 |
| GastroenteritisInfections and infestations | 2/79 |
| Urinary tract infectionInfections and infestations | 2/79 |
| PyrexiaGeneral disorders | 2/79 |
| HyperglycaemiaMetabolism and nutrition disorders | 2/79 |
| Event | Sirolimus (SRL) |
|---|---|
| ConstipationGastrointestinal disorders | 31/79 |
| Blood cholesterol increasedInvestigations | 29/79 |
| Upper respiratory tract infectionInfections and infestations | 26/79 |
| Procedural painInjury, poisoning and procedural complications | 24/79 |
| DiarrhoeaGastrointestinal disorders | 21/79 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 19/79 |
| AnaemiaBlood and lymphatic system disorders | 19/79 |
| AcneSkin and subcutaneous tissue disorders | 18/79 |
| Alanine aminotransferase increasedInvestigations | 17/79 |
| NauseaGastrointestinal disorders | 16/79 |
| Age Continuous(years) | Sirolimus (SRL) |
|---|---|
| Mean | 40.16 ± 12.69 |
| Sex: Female, Male(Participants) | Sirolimus (SRL) |
|---|---|
| Female | 47 |
| Male | 32 |
The record gives a start of Mar 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sirolimus
Wyeth is now a wholly owned subsidiary of Pfizer →